

Cabotegravir (CAB-LA) for PrEP

Updated October 2024

Educational Resources for Healthcare Professionals

- HIV BLUPrint: [CAB-LA Resources](#)
 - American Academy of HIV Medicine: [Long-Acting Agent Resource Center](#)
 - American Academy of HIV Medicine: [Injectable PrEP Guidelines](#)
 - California PTC: [Injectable PrEP Learning Community Resources](#)
 - Denver PTC:
 - [Options for HIV PrEP](#)
 - [Denver Sexual Health Clinic HIV PrEP Clinical Guideline](#)
-

Accessing Medication

- [ViiV Resources](#)
 - [Prescribing Information](#)
 - [Dosing and Drug Interactions](#)
 - [Medication Access and Patient Support](#)
 - Includes medication acquisition options
 - Speciality Pharmacy
 - Buy and Bill
 - [Resources for Healthcare Providers](#)
 - [Apretude Ordering Guide](#)
-

Cabotegravir (CAB-LA) for PrEP

Updated October 2024

Prescribing Information: The below tables are from the medication package insert.

Dosing/Administration:

1. Direct to Injection Dosing Schedule:

Table 2. Recommended Dosing Schedule (Direct to Injection) for Pre-exposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg

Intramuscular (Gluteal) Initiation Injection (Month 1 and Month 2)	Intramuscular (Gluteal) Continuation Injection (Month 4 and Every 2 Months Onwards)
APRETUDE ^a 600 mg (3 mL)	APRETUDE ^a 600 mg (3 mL)

^a Individuals may be given APRETUDE up to 7 days before or after the date the individual is scheduled to receive the injections.

2. Dosing with Optional Oral Lead In:

Dosing with OPTIONAL oral lead in

Table 1. Recommended Dosing Schedule (with Oral Lead-in) for Pre-exposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg

Oral Lead-in (at Least 28 Days)	Intramuscular (Gluteal) Initiation Injection (Month 2 and Month 3)	Intramuscular (Gluteal) Continuation Injection (Month 5 and Every 2 Months Onwards)
Oral cabotegravir 30 mg by mouth once daily for 28 days	APRETUDE ^a 600 mg (3 mL)	APRETUDE ^b 600 mg (3 mL)

^a Should be administered on the last day of oral lead-in or within 3 days thereafter.

^b Individuals may be given APRETUDE up to 7 days before or after the date the individual is scheduled to receive the injections.

Cabotegravir (CAB-LA) for PrEP

Updated October 2024

3. Dosing After Missed Injections:

Table 3. Injection Dosing Recommendations after Missed Injections

Time since Last Injection	Recommendation
If second injection is missed and time since first injection is:	
Less than or equal to 2 months	Administer 600-mg (3-mL) gluteal intramuscular injection of APRETUDE as soon as possible, then continue to follow the every-2-month injection dosing schedule.
Greater than 2 months	Restart with 600-mg (3-mL) gluteal intramuscular injection of APRETUDE, followed by a second 600-mg (3-mL) initiation injection dose 1 month later. Then continue to follow the every-2-month injection dosing schedule thereafter.
If third or subsequent injection is missed and time since prior injection is:	
Less than or equal to 3 months	Administer 600-mg (3-mL) intramuscular injection of APRETUDE as soon as possible, then continue with the every-2-month injection dosing schedule.
Greater than 3 months	Restart with 600-mg (3-mL) gluteal intramuscular injection of APRETUDE, followed by the second 600-mg (3-mL) initiation injection dose 1 month later. Then continue with the every-2-month injection dosing schedule thereafter.

CAB-LA Considerations

Potential Risk of Resistance with Apretude

There is a potential risk of developing resistance to Apretude if an individual acquires HIV-1 either before or while taking Apretude or following discontinuation of Apretude. To minimize this risk, it is essential to clinically reassess individuals for risk of HIV-1 acquisition and to **test before each injection** to confirm HIV-1 negative status. Individuals who are confirmed to have HIV-1 infection must transition to a complete HIV-1 treatment regimen.

Alternative forms of PrEP should be considered following discontinuation of Apretude for those individuals at continuing risk of HIV-1 acquisition and initiated within 2 months of the final injection of Apretude.

Cabotegravir (CAB-LA) for PrEP

Updated October 2024

Patient Assistance Programs

Read more [here](#).

1. [Apretude Savings Program](#)

The Apretude Savings Program may help consumers with their out-of-pocket costs for prescribed Apretude.

- The program is for commercially insured consumers prescribed Apretude
- If approved, consumers may pay as little as \$0 copay
- Consumers must be a resident of the United States or US territories
- Up to \$7,850 every calendar year.
- Medicare-eligible consumers and consumers enrolled in government-funded programs are not eligible.

2. [Patient Assistance Program \(PAP\)](#)

Eligibility for PAP, patients must:

- Live in one of the 50 states, the District of Columbia, or Puerto Rico
- Have a household income less than or equal to 500% of the Federal Poverty Level based on household size
- Not be eligible for Medicaid or Puerto Rico's Government Health Plan, Mi Salud

And either:

- Have no prescription drug coverage, or
- Have a Medicare Part B, Medicare Part D, or Medicare Advantage Plan, and have spent at least \$600 or more on out-of-pocket prescription expenses during the current calendar year, or
- Have a private insurance plan limited to generic-only coverage, outpatient use only, or therapeutic class exclusion (non-coverage) of drug